- Home
- ED vs ARGX Comparison
ED vs ARGX Comparison
Compare ED & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ED
- ARGX
- Stock Information
- Founded
- ED 1884
- ARGX 2008
- Country
- ED United States
- ARGX Netherlands
- Employees
- ED N/A
- ARGX N/A
- Industry
- ED Power Generation
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ED Utilities
- ARGX Health Care
- Exchange
- ED Nasdaq
- ARGX Nasdaq
- Market Cap
- ED 39.6B
- ARGX 40.4B
- IPO Year
- ED N/A
- ARGX 2017
- Fundamental
- Price
- ED $112.10
- ARGX $596.20
- Analyst Decision
- ED Hold
- ARGX Strong Buy
- Analyst Count
- ED 9
- ARGX 20
- Target Price
- ED $102.11
- ARGX $699.56
- AVG Volume (30 Days)
- ED 3.0M
- ARGX 465.0K
- Earning Date
- ED 05-01-2025
- ARGX 05-08-2025
- Dividend Yield
- ED 3.05%
- ARGX N/A
- EPS Growth
- ED N/A
- ARGX N/A
- EPS
- ED 5.24
- ARGX 12.78
- Revenue
- ED $15,256,000,000.00
- ARGX $2,248,205,000.00
- Revenue This Year
- ED $8.01
- ARGX $57.86
- Revenue Next Year
- ED $3.81
- ARGX $31.90
- P/E Ratio
- ED $21.39
- ARGX $43.64
- Revenue Growth
- ED 4.04
- ARGX 77.22
- 52 Week Low
- ED $87.28
- ARGX $352.77
- 52 Week High
- ED $114.87
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- ED 61.89
- ARGX 51.80
- Support Level
- ED $111.06
- ARGX $583.00
- Resistance Level
- ED $114.87
- ARGX $610.06
- Average True Range (ATR)
- ED 3.11
- ARGX 24.42
- MACD
- ED 0.05
- ARGX 4.74
- Stochastic Oscillator
- ED 76.10
- ARGX 84.66
About ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.